

Chikata T, Carlson J, Tamura Y, Borghan M, Naruto T, Hashimoto M, Murakoshi H, Le A, Mallal S, John M, Gatanaga H, Oka S, Brumme Z, and Takiguchi M.

Host-specific adaptation of HIV-1 subtype B in the Japanese population.

J Virol. 88(9): 4764-4775, 2014.

Nishijima T, Gatanaga H, Teruya K, Mizushima D, Aoki T, Watanabe K, Kinai E, Honda H, Yazaki H, Tanuma J, Tsukada K, Kikuchi Y, and Oka S.

Skin rash induced by ritonavir-boosted darunavir is common, but generally tolerable in an observational setting.

J Infect Chemothera. 20(4): 285-287, 2014.

Tanuma J, Quang VM, Joya A, Hachiya A, Watanabe K, Gatanaga H, Chau NVV, Chinh NT, and Oka S.

Low prevalence of drug resistant HIV-1 transmission while antiretroviral therapy was scaling up in Southern Vietnam in 2008-2012.

JAIDS. 66(4): 358-364, 2014.

Tsuchiya K, Hayashida T, Hamada A, Kato S, Oka S, and Gatanaga H.

Low raltegravir concentration in cerebrospinal fluid in patients with ABCG2 genetic variants.

JAIDS. 66(5): 484-486, 2014.

Sun X, Fujiwara M, Shi Y, Kuse N, Gatanaga H, Appay V, Gao GF, Oka S, and Takiguchi M.

Superimposed epitopes restricted by the same HLA molecule drive distinct HIV-specific CD8⁺ T cell repertoires.

J Immunol. 193: 77-84, 2014.

Ishikane M, Watanabe K, Tsukada K, Nozaki Y, Yanase M, Igari T, Masaki N, Kikuchi Y, Oka S, and Gatanaga H.

Acute Hepatitis C in HIV-1 infected Japanese cohort.

PLOS One. 9(6): e100517, 2014.

Nishijima T, Kawasaki Y, Tanaka N, Tanuma J, Tsukada K, Teruya K, Kikuchi Y, Gatanaga H, and Oka S.

Long-term tenofovir exposure consistently deteriorates renal function in HIV-1-infected patients with low body weight: results from 10 years of observational cohort.

AIDS. 28(13): 1903-1910, 2014.

Nishijima T, Tsuchiya K, Tanaka N, Joya A, Hamada Y, Mizushima D, Aoki T, Watanabe K, Kinai E, Honda H, Yazaki H, Tanuma J, Tsukada K, Teruya K, Kikuchi Y, Oka S, and Gatanaga H.

Single nucleotide polymorphisms in UDP-glucuronosyltransferase 1A-3'untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: A pharmacogenetic study.

J Antimicrob Chemothera. 69(12): 3320-3328, 2014.

Watanabe K, Nagata N, Sekine K, Watanabe K, Igari T, Tanuma J, Kikuchi Y, Oka S, Gatanaga H.

Asymptomatic Intestinal Amebiasis in Japanese HIV-1-Infected Individuals.

Am J Trop Med Hyg. 91(4): 816-820, 2014.

Nishijima T, Gatanaga H, Teruya K, Tajima T, Kikuchi Y, Hasuo K, Oka S.

Brain magnetic resonance imaging screening is not useful for HIV-1-infected patients without neurological symptoms.

AIDS Res Hum Retrovirus. 30(10): 970-974, 2014.

Mizushima D, Tanuma J, Gatanaga H, Lam NT, Dung NTH, Kinh NV, Kikuchi Y, and Oka S. Low body weight and tenofovir use are risk factors for renal dysfunction in Vietnamese HIV-infected patients. A prospective 18-month observation study.

J Infect Chemothera. 20(12): 784-788, 2014.

Aoki A, Moro H, Watanabe T, Asakawa K, Miura S, Moriyama M, Tanabe Y, Kagamu H, Narita I. A case of severe thrombocytopenia associated with acute HIV-1 infection.

Int J STD AIDS. 2014.

Watanabe T, Hamada-Tsutsumi S, Yokomaku Y, Imamura J, Sugiura W, Tanaka Y. Post-Exposure Prophylactic Effect of HBV-active Antiretroviral Therapy Against Hepatitis B Virus Infection.

Antimicrobial agents and chemotherapy. 59(2): 1292-8, 2015.

Shiino T, Hattori J, Yokomaku Y, Iwatani Y, Sugiura W.

Phylogenetic Analysis Reveals CRF01_AE Dissemination between Japan and Neighboring Asian Countries and the Role of Intravenous Drug Use in Transmission.

PloS one. 9(7): e102633, 2014.

Imahashi M, Izumi T, Watanabe D, Imamura J, Matsuoka K, Ode H, Masaoka T, Sato K, Kaneko N, Ichikawa S, Koyanagi Y, Takaori-Kondo A, Utsumi M, Yokomaku Y, Shirasaka T, Sugiura W, Iwatani Y, Naoe T.

Lack of Association between Intact/Deletion Polymorphisms of the APOBEC3B Gene and HIV-1 Risk.

PloS one. 9(3): e92861, 2014.

Ota Y, Hishima T, Mochizuki M, Kodama Y, Moritani S, Oyaizu N, Mine S, Ajisawa A, Tanuma J, Uehira T, Hagiwara S, Yajima K, Koizumi Y, Shirasaka T, Kojima Y, Nagai H, Yokomaku Y, Shiozawa Y, Koibuchi T, Iwamoto A, Oka S, Hasegawa H, Okada S, Katano H.

Classification of AIDS-related lymphoma cases between 1987 and 2012 in Japan based on the WHO classification of lymphomas, fourth edition.

Cancer medicine. 3(1): 143-153, 2014.

Katano H, Hishima T, Mochizuki M, Kodama Y, Oyaizu N, Ota Y, Mine S, Igari T, Ajisawa A, Teruya K, Tanuma J, Kikuchi Y, Uehira T, Shirasaka T, Koibuchi T, Iwamoto A, Oka S, Hasegawa H, Okada S, Yasuoka A.

The prevalence of opportunistic infections and malignancies in autopsied patients with human immunodeficiency virus infection in Japan.

BMC Infect Dis. 14: 229. Published online 2014 Apr.

Yajima K, Uehira T, Otera H, Koizumi Y, Watanabe D, Kodama Y, Kuzushita N, Nishida Y, Mita E, Mano M, and Shirasaka T.

A case of non-cirrhotic portal hypertension associated with anti-retroviral therapy in a Japanese patient with human immunodeficiency virus infection.

J Infect Chemother. 20(9): 582-5, 2014.

Ogawa Y, Watanabe D, Hirota K, Ikuma M, Yajima K, Kasai D, Mori K, Ota Y, Nishida Y, Uehira T, Mano M, Yamane T, and Shirasaka T.

Rapid multiorgan failure due to large B-cell lymphoma arising in human herpesvirus-8-associated multicentric Castleman disease in a human immunodeficiency virus-infected patient.

Intern Med. 253(24): 2805-9, 2014.

Furukawa Y, Hashiguchi T, Minami R, Yamamoto M, Takashima H.

Exacerbation of microcytic anemia associated with cessation of anti-retroviral therapy in an HIV-1-infected patient with beta thalassemia.

J Infect Chemother. 20(6): 387-389. Jun, 2014.

Nishijima Takeshi, Takano Misao, Ishisaka Michiyo, Komatsu Hirokazu, Gatanaga Hiroyuki, Kikuchi Yoshimi, Endo Tomoyuki, Horiba Masahide, Kaneda Satoru, Uchiyama Hideki, Koibuchi Tomohiko, Naito Toshio, Yoshida Masaki, Tachikawa Natsuo, Ueda Mikio, Yokomaku Yoshiyuki, Fujii Teruhisa, Higasa Satoshi, Takada Kiyonori, Yamamoto Masahiro, Matsushita Shuzo, Tateyama Masao, Tanabe Yoshinari, Mitsuya Hiroaki, Oka Shinichi, The epizicom-Truvada study team.

Abacavir/Lamivudine versus Tenofovir/Emtricitabine with Atazanavir/Ritonavir for Treatment-naïve Japanese Patients with HIV-1 Infection: A Randomized Multicenter Trial.

Internal Medicine. (0918-2918)52 卷 7 号 Page735-744(2013.04).

Nishijima Takeshi, Gatanaga Hiroyuki, Shimbo Takuro, Komatsu Hirokazu, Endo Tomoyuki, Horiba Masahide, Koga Michiko, Naito Toshio, Itoda Ichiro, Tei Masanori, Fujii Teruhisa, Takada Kiyonori, Yamamoto Masahiro, Miyakawa Toshikazu, Tanabe Yoshinari, Mitsuya Hiroaki, Oka Shinichi, team the SPARE study.

Switching Tenofovir/Emtricitabine plus Lopinavir/r to Raltegravir plus Darunavir/r in Patients with Suppressed Viral Load Did Not Result in Improvement of Renal Function but Could Sustain Viral Suppression: A Randomized Multicenter Trial.

PLoS One. Volume: 8(8) 8,2013.

Tomoko Omiya, Yoshihiko Yamazaki, Megumi Shimada, Kazuko Ikeda, Seiko Ishiuti-Ishitani, Yoko Sumikawa, Tsuno and Katsumi Ohira.

Mental health of patients with human immunodeficiency virus in Japan :a comparative analysis of employed and unemployed patients.

AIDS Care. Vol.26,No.11,1370-1378, 2014.

Kuse, Akahoshi, Gatanaga, Ueno, Oka, Takiguchi.

Selection of T18-8V mutant associated with long-term control of HIV-1 by cross-reactive HLA-B*51:01-restricted cytotoxic T cells.

Journal of Immunology. 193(10): 4814-4822, 2014.

Eguchi, Takatsuki, Soyama, Hidaka, Nakao, Shirasaka, Yamamoto, Tachikawa, Gatanaga, Kugiyama, Yatsunami, Ichida, Kokudo.

Analysis of the hepatic functional reserve, portal hypertension, and prognosis of patients with human immunodeficiency virus/hepatitis C virus coinfection through contaminated blood products in Japan.

Transplantation Proceedings. 46(3): 736-738, 2014.

Rahman, Kuse, Murakoshi, Chikata, Gatanaga, Oka, Takiguchi.

Raltegravir and elvitegravir-resistance mutation E92Q affects HLA-B*40:02-restricted HIV-1-specific CTL recognition.

Microbes and Infection. 16(5): 434-438, 2014.

Sakurai, D, Iwatani, Y, Ohtani, H, Naruse, T, Terunuma, H, Sugiura, W, Kimura, A.

APOBEC3H polymorphisms associated with the susceptibility to HIV-1 infection and AIDS progression in Japanese.

Immunogenetics. 2015(in press).

Yoshida S, Hattori J, Matsuda M, Okada K, Kazuyama Y, Hashimoto O, Ibe S, Fujisawa SI, Chiba H, Tatsumi M, Kato S, Sugiura W.

Japanese External Quality Assessment Program to Standardize HIV-1 Drug-Resistance Testing (JEQS2010 Program) Using In Vitro Transcribed RNA as Reference Material.

AIDS research and human retroviruses. 2014(in press).

Kudoh A, Takahama S, Sawasaki T, Ode H, Yokoyama M, Okayama A, Ishikawa A, Miyakawa K, Matsunaga S, Kimura H, Sugiura W, Sato H, Hirano H, Ohno S, Yamamoto N, Ryo A.

The phosphorylation of HIV-1 Gag by atypical protein kinase C facilitates viral infectivity by promoting Vpr incorporation into virions.

Retrovirology. 11: 9, 2014.

Gu L, Kawana-Tachikawa A, Shiino T, Nakamura H, Koga M, Kikuchi T, Adachi E, Koibuchi T, Ishida T, Gao GF, Matsushita M, Sugiura W, Iwamoto A, Hosoya N.

Development and Customization of a Color-Coded Microbeads-Based Assay for Drug Resistance in HIV-1 Reverse Transcriptase.

PloS one. 9(10): e109823, 2014.

Hiroki Yagura, Mayu Shibata¹, Hiroyuki Kushida, Munehiro Yoshino, Izumi Nakata, Tomoko Uehira, Shin-ya Morita, Takuma Shirasaka, Reiko Teraoka, Takeshi Kuwahara, Shuji Kitagawa, Thermal Stability of Tenofovir Disoproxil Fumarate in Suspension.

Jpn J Pharm Health Care Sci. 40(4): 230-236, 2014 年.

佐藤麻希、阿部憲介、山本善彦、諏江裕、伊藤俊広。

東日本大震災の経験から考える災害時の抗 HIV 薬供給と服薬支援策の課題。

日本エイズ学会誌. 16: 105-109, 2014.

阿部憲介、佐藤麻希、神尾咲留未、小山田光孝、塚本琢也、佐々木晃子、伊藤ひとみ、佐藤功、伊藤俊広。

当院における TDF 関連高 CK 血症の検討。

仙台医療センター医学雑誌. 4: 20-24, 2014.

木村哲、山本政弘、橋野聡、伊藤俊広、上平朝子。

HIV 感染症の検査・診断・治療における『連携』の諸問題を考える（座談会）。

医薬の門. 53: 356-365, 2014.

豊嶋崇徳。

「HIV・HCV 重複感染症診療ガイドライン 改訂第 6 版」。(平成 26 年 12 月刊行)。

編集：北海道大学病院 HIV・HCV 重複感染症診療委員会。

豊嶋崇徳。

「HIV・HCV 重複感染患者さんの手引き Heartec 改訂第 6 版」(平成 26 年 12 月刊行)。

編集：北海道大学病院 HIV・HCV 重複感染症診療委員会。

遠藤知之、藤本勝也、南昭子、吉田美穂、竹村龍、渡部恵子、坂本玲子、武内阿味、近藤健、橋野聡、清水力、豊嶋崇徳。

当院における HIV 感染者のビタミン D の検討。

日本エイズ学会誌. (in press).

永井孝宏、児玉泰光、黒川亮、山田瑛子、村山正晃、池野良、田邊嘉也、高木律男。

新潟大学医歯学総合病院歯科における HIV 感染症患者の臨床的検討。

日本エイズ学会誌. 16: 148-154, 2014.

白阪琢磨.

服薬をはじめるまえに第5版.

鳥居薬品(株)患者様用服薬支援冊子. (2014年5月).

白阪琢磨.

座談会「新しい治療ガイドラインーHIV初感染・妊婦の治療、職業的HIV曝露時の感染予防も含めてー」.

HIV感染症とAIDSの治療. 5(1)4-12 (2014年5月).

矢嶋敬史郎、白阪琢磨.

連載 エイズに見られる感染症と悪性腫瘍(9) サルモネラ菌血症.

化学療法領域. 30(7) (2014年7月).

白阪琢磨.

座談会「HIV感染症治療ガイドラインを考察する」.

ヴィーブヘルスケア(株)座談会記録集. 2014年9月.

白阪琢磨.

透析医療者のためのHIV感染症の知識～長期療養時代を見据えて～.

鳥居薬品 第59回日本透析医学会学術集会・総会ランチョンセミナー15 記録冊子「医薬の門」. 54(5)2-6 (2014年11月).

白阪琢磨.

特集2「新規HIV感染者は過去2位。新規AIDS患者は過去最多。伸び率が高いのは、50代以上です」.

健. 43(9)22-23 (2014年12月).

吉岡巖、金宮健翁、木下竜弥、鄭則秀、原田泰規、上平朝子、白阪琢磨、岡聖次.

抗HIV薬Atazanavir内服患者に発生した尿路結石症の検討.

泌尿器外科. 27(11): 1823-1827 (2014年11月).

白阪琢磨.

第4章 治療と管理・対応「抗HIV-1療法: いつ、どのように開始するか」.

最新医学別冊「新しい診断と治療のABC65HIV感染症とAIDS改訂第2版」. 2014年12月発行予定.

白阪琢磨.

抗HIV用薬.

治療薬ハンドブック2015. 株式会社じほう (2015年2月).

塩野徳史 (名古屋市立大学 看護学部国際保健看護学)、金子典代、市川誠一、山本政弘、健山正男、内海眞、木村哲、生島嗣、鬼塚哲郎.

MSM (Men who have sex with men) におけるHIV抗体検査受検行動と受検意図の促進要因に関する研究.

日本公衆衛生雑誌. (0546-1766)60巻10号 Page639-650(2013.10).

山本政弘.

精神科合併症ーうつ(気分障害)、薬物依存ー.

HIV感染症とAIDSの治療. 5巻1号, 57-59 2014.

辻麻理子、山本政弘、外川正生、井村弘子、和田裕一、塚原優己。
HIV 母子感染児の告知支援に関する解析と対策の評価。
日本エイズ学会誌. vol.16 No.3 176-183 2014 (8) .

宇佐美雄司。

歯科の医療体制整備に関する研究班：HIV 感染症歯科診療ネットワーク取組事例集（改訂版）。
2014 年。

佐藤淳。

歯科医院における院内感染対策の基礎知識。
月刊保団連. 1175 号: 10-15, 2014.

吉川博政、山本政弘、城崎真弓、長与由紀子、辻麻里子、前田憲昭。

九州医療センターにおける歯科医師、歯科衛生士 HIV/AIDS 研修プログラムについて。
日本エイズ学会誌. 16(2): 110-114, 2014.

宮田泰。

愛知県歯科医師会における院内感染予防対策への取り組み。
日本歯科評論. 別冊「患者が求める医療安全、院内感染対策」: 160-167, 2014.

宇佐美雄司。

いま HIV/エイズはどうなっているか。
日本歯科評論. 平成 27 年 3 月号, 2015(in press).

山中京子。

他者との協働：他職種連携の課題とその可能性。
児島亜紀子, 『主体と他者』。ミネルヴァ書房. 京都. 2015（現在印刷中）。

高田知恵子。

秋田県における HIV カウンセリングの構築と展開ー地方における地域心理臨床の実践ー。
秋田大学教育文化学部研究紀要, 人文科学・社会科学部門. 69: pp53-61, 2014.

岩崎晋也、田中千枝子他。

医療ソーシャルワーク。
社会福祉のフロンティア. 有斐閣. pp189-194, 2014.

國本雄介、吉野宗宏、大石裕樹、原田幸子、井上正朝、佐藤麻希、内山真理子、齋藤直美、丸山一郎、
下川千賀子、畝井浩子、松本俊治、増田純一、千田昌之、和泉啓司郎、宮本篤。

HIV 感染症診療における薬剤師介入が医療者側へもたらす効果に関する実態調査ーエイズ治療ブ
ック拠点病院および ACC における検討ー。
医療薬学. 40(8): 471-479, 2014 年。

研究成果の別刷

Incidence and Risk Factors for Incident Hepatitis C Infection Among Men Who Have Sex With Men With HIV-1 Infection in a Large Urban HIV Clinic in Tokyo

Takeshi Nishijima, MD,*† Takuro Shimbo, MD, PhD,‡ Hirokazu Komatsu, MD, PhD,§ Yohei Hamada, MD,* Hiroyuki Gatanaga, MD, PhD,*† and Shinichi Oka, MD, PhD*†

Background: The epidemiology of hepatitis C virus (HCV) infection among HIV-infected men who have sex with men (MSM) who do not inject drugs in Asia remains unknown.

Method: The incidence and risk factors for incident HCV infection among HIV-infected MSM at a large HIV clinic in Tokyo were elucidated. Poisson regression compared the incidence of HCV seroconversion at different observation periods.

Results: Of 753 HIV-1 infected MSM patients negative for HCV antibody (HCVAb) at baseline and available follow-up HCVAb test, 21 patients (2.8%) seroconverted to HCVAb positive over 2246 person-years (PY), for an incidence of 9.35 per 1000 PY. The incidence increased over time from 0 per 1000 PY in 2005–2006, 3.0 per 1000 PY in 2007–2008, 7.7 per 1000 PY in 2009–2010, to 24.9 per 1000 PY in 2011–2012 ($P = 0.012$). Of 21 incident cases, only 4 (19%) were injection drug users, and sensitivity analysis that excluded injection drug users yielded similar findings. Multivariate analysis identified illicit drug use to be an independent risk for HCV infection (hazard ratio = 3.006; 95% confidence interval: 1.092 to 8.275; $P = 0.033$).

Conclusions: Incident HCV infection is increasing among HIV-1-infected MSM noninjection drug users at resource-rich setting in Asia. Illicit drug use is an independent risk factor for incident HCV infection in this population.

Key Words: incident HCV infection, illicit drug use, injection drug use, men who have sex with men, Tokyo, Asia

(*J Acquir Immune Defic Syndr* 2014;65:213–217)

INTRODUCTION

Coinfection with hepatitis C virus (HCV) in patients with HIV-1 infection is one of the major comorbidities and associates with worsened mortality.^{1–6} Although HCV infection is especially common among injection drug users because of transparental infection,⁷ noninjection illicit drug use and traumatic sexual behavior in the absence of injection drug use are reported in the United States and Europe to enhance noninjection drug-related transmission of HCV.^{8–14}

In Japan, because of the low prevalence of injection drug use in the general population (lifetime prevalence of illicit drug use as a whole in 2009 was only 2.9%), coinfection with HCV in patients with HIV-1 infection is rare.^{15–18} Recently, however, at our clinic, the AIDS Clinical Center, Tokyo, there has been a surge in the rate of acute HCV infection among men who have sex with men (MSM) with HIV-1 infection who deny using injection drugs. The AIDS Clinical Center is one of the largest referral centers for HIV care in Japan with patients mostly comprising MSM.¹⁹

This study was designed to determine the incidence and risk factors of incident HCV infection in MSM with HIV-1 infection at a resource-rich setting in Asia, with a special focus on noninjection illicit drug use.

METHODS

Study Subjects

The study population was HIV-1-infected MSM, aged older than 17 years, who visited our clinic for the first time from January 2005 to December 2010, and with negative HCV antibody (HCVAb) at baseline and at least 1 subsequent HCVAb test result. The following exclusion criteria were applied: (1) patients who visited the clinic for a second opinion, (2) patients referred to other facilities on their first or second visit. The study patients were followed up until December 31, 2012.

Received for publication July 3, 2013; accepted October 22, 2013.

From the *AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan; †Center for AIDS Research, Kumamoto University, Kumamoto, Japan; ‡Department of Clinical Study and Informatics, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan; and §Department of Community Care, Saku Central Hospital, Nagano, Japan.

Supported by a Grant-in Aid for AIDS research from the Japanese Ministry of Health, Labour, and Welfare (Grant H23-AIDS-001).

Study design: T.N., T.S., H.K., and Y.H.; data collection: T.N. and H.G.; data interpretation: T.N., T.S., and H.K.; and drafting and critical revision of manuscript: T.N., H.G., and S.O. All authors have read and approved the text submitted.

The authors have no funding or conflicts of interest to disclose.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.jaids.com).

Correspondence to: Hiroyuki Gatanaga, MD, PhD, AIDS Clinical Center, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku, Tokyo 162-0052, Japan (e-mail: higatana@acc.ncgm.go.jp).

Copyright © 2013 by Lippincott Williams & Wilkins

Measurements

At our clinic, HCVAb, CD4 cell count, HIV-1 viral load, hepatitis B surface antigen (HBsAg), and *Treponema pallidum* latex agglutination (TPHA) test are routinely conducted on the first visit. Patients positive for HCVAb subsequently undergo another HCV-RNA measurement. Patients visit our clinic at least every 3 months for monitoring CD4 cell count, HIV-1 viral load, and liver function tests, because the prescription period under the Japanese health care system is limited to 3 months. Repeat HCVAb tests were performed at the discretion of the treating physician. Laboratory data and baseline demographics on the first visit were collected from the medical records.

Social demographics including sexuality and history and type of illicit drug used (injection or noninjection) were collected through a structured interview conducted on the first visit.²⁰ Because the interview could underestimate the prevalence of illicit drug use, we also searched the medical records for information on illicit drug use and related variables covering the period from the first visit to December 2012.

At our clinic, written informed consent is obtained from each patient to store serum samples drawn at the first visit and subsequent visits at the discretion of the treating physician.²¹ Either latest HCVAb test result conducted in clinical practice or from the latest stored serum sample was used to determine the status of HCV infection, whichever the follow-up time was longer. This study was approved by the Human Research Ethics Committee of the hospital.

Statistical Analysis

The incidence of HCV was calculated by dividing the number of HCVAb seroconversion by person-time at risk. Person-time represented the time from the first visit to the first

positive HCVAb in patients diagnosed with incident HCV infection and the time from the first visit to the last negative HCVAb result in patients without incident infection. Poisson regression was used to compare the incidence of HCV seroconversion among 4 observation periods.

The uni- and multivariate Cox proportional hazards model was used to estimate the impact of illicit drug use as a whole over nonusers on the incidence of HCV infection as a primary exposure.

In multivariate analysis, age was added to the univariate analysis for illicit drug use over nonuse to form model 2. In model 3, injection drug use and insurance status were added because of their significant association with incident HCV infection in univariate analysis. Methamphetamine use and incarceration because of drugs were not added because of their multicollinearity with injection drug use (most injection drug users in Japan use methamphetamine injection).¹⁸ Baseline CD4 count, HBsAg, and TPHA were added to the model because previous studies showed that low CD4 count and these infections are risk factors.^{6,22}

Statistical significance was defined at 2-sided *P* values of <0.05. We used the hazard ratios (HRs) and 95% confidence intervals (95% CIs) to estimate the impact of each variable on the incidence of HCV infection. All statistical analyses were performed with the Statistical Package for Social Sciences version 20.0 (SPSS, Chicago, IL).

RESULTS

A total of 1182 MSM patients with HIV-1 infection visited the AIDS Clinical Center for the first time during the study inclusion period. Of these, 114 patients were excluded from the analysis (Fig. 1). The remaining 1068 patients had baseline HCVAb results, of whom 22 were positive for




FIGURE 1. Patient enrollment process.

TABLE 1. Baseline Characteristics of Patients With and Without Incident HCV Infection

	All (n = 753)	Incident HCV (n = 21)	HCV-free (n = 732)	P
Median (IQR) age (yrs)	35 (29–41)	35 (32–42)	35 (29–41)	0.951
Illicit drug use, n (%)	298 (40)	15 (71)	283 (39)	0.003
Injection drug use, n (%)	37 (5)	4 (19)	33 (5)	0.016
Methamphetamine use, n (%)	48 (6)	4 (19)	44 (6)	0.039
Arrest due to illicit drug use, n (%)	24 (3)	3 (14)	21 (3)	0.026
Median (IQR) CD4 count (/μL)	244 (100–365)	311 (159–391)	244 (98–364)	0.539
Median (IQR) HIV-1 viral load (log ₁₀ /mL)	4.69 (4.00–5.20)	4.54 (3.51–4.97)	4.69 (4.00–5.22)	0.110
AIDS, n (%)	223 (30)	7 (33)	216 (30)	0.809
Positivity for hepatitis B surface antigen	48 (6)	2 (10)	46 (6)	0.638
Positivity for TPHA	236 (31)	8 (38)	228 (31)	0.483
On antiretroviral therapy, n (%)	66 (9)	3 (14)	63 (9)	0.419
Ethnicity, n (%)				0.537
Japanese	712 (95)	21 (100)	691 (94)	
Other Asian	20 (3)	0	20 (3)	
White	21 (3)	0	21 (3)	
Health insurance status, n (%)				0.003
With insurance	704 (94)	16 (76)	688 (94)	
No insurance	15 (2)	1 (5)	14 (2)	
On social benefits	34 (5)	4 (19)	30 (4)	
Median (IQR) follow-up days	984 (539–1557)	852 (324–1491)	997 (543–1562)	0.334

Patients' characteristics and social demographics were compared between those with incident HCV infection and those without such infection by the Student *t* test for continuous variables and by either the χ^2 test or Fisher exact test for categorical variables.

HCVAb. Of 1046 HIV-1 infected MSM patients with negative baseline HCVAb, the follow-up HCVAb test was available for 753 (72%) patients, either with clinical data (n = 295) or with stored blood samples (n = 458). The study population comprised the latter group of 753 patients.

Twenty-one patients (2.8%) incidentally seroconverted to HCVAb positive over 2246 person-years (PY) of total observation period, with an incidence of 9.35 per 1000 PY (95% CI: 6.12 to 14.2). The median time from the first visit to HCV seroconversion was 852 days [interquartile range (IQR), 324–1491 days]. The incidence increased over time from 0 per 1000 PY (0 case/270 PY) in 2005–2006, 3.0 per 1000 PY (2/672 PY) in 2007–2008, 7.7 per 1000 PY (6/779 PY) in 2009–2010, to 24.9 per 1000 PY (13/522 PY) in 2011–2012 (*P* = 0.012). As sensitivity analysis, the same calculations were conducted for the study population excluding injection drug users, and the results were similar; 17 patients became HCVAb positive over 2146 PY for an incidence of 7.92 per 1000 PY, and the incidence increased over time [0/1000 PY (0/258 PY) in 2005–2006, 1.5/1000 PY (1/650 PY) in 2007–2008, 8.0/1000 PY (6/747 PY) in 2009–2010, and 20.2/1000 PY (10/495 PY) in 2011–2012 (*P* = 0.045)].

The study patients were mostly Japanese men of relatively young age, covered with health insurance (Table 1); 40% of the study patients were illicit drug users based on the interview and medical records. Amyl nitrite, 5-methoxy-diisopropyltryptamine, 3,4-methylenedioxymethamphetamine, cannabis, heroin, cocaine, and opium were named by the patients. Patients with incident HCV infection were significantly more likely to be illicit drug users (*P* = 0.003). In addition, incident HCV cases were more likely to be injection drug users

(*P* = 0.016), methamphetamine users (*P* = 0.039), and incarcerated owing to illicit drug use (*P* = 0.026) (Table 1). In contrast to the high prevalence of illicit drug use (40%), the prevalence of injection drug use was low (5%).

Among the 21 HCV incident cases, only 4 (19%) patients were injection drug users. Of the 21, 18 patients were screened for HCVAb because of high serum alanine aminotransferase levels, including all 17 positive for HCV RNA.

Among illicit drug users (n = 298) and nonusers (n = 455), 15 (5.0%) and 6 (1.3%) patients, respectively, were infected with HCV, with incidence of 16.6 and 4.48 per 1000 PY, respectively. Illicit drug users were significantly more likely to be infected with HCV, compared with nonusers (*P* = 0.004, Log-rank test). The total observation period was 906 PY (median, 1012 days; IQR, 543–1607 days) for illicit drug users and 1340 PY (median, 963 days; IQR, 538–1542 days) for nonusers.

Univariate analysis showed a significant relationship between illicit drug use and incident HCV infection (HR = 3.662; 95% CI: 1.420 to 9.439; *P* = 0.007) (see **Table S1, Supplemental Digital Content**, <http://links.lww.com/QAI/A479>). Furthermore, injection drug use (HR = 5.387; 95% CI: 1.804 to 16.09; *P* = 0.003), methamphetamine use (HR = 3.220; 95% CI: 1.083 to 9.573; *P* = 0.035), incarceration owing to illicit drugs (HR = 4.857; 95% CI: 1.429 to 16.51; *P* = 0.011), and on social benefits (government financial assistance) (HR = 6.982; 95% CI: 2.308 to 21.12; *P* = 0.001) were significantly associated with incident HCV infection. Conversely, age, low baseline CD4 count, positive HBsAg, and positive TPHA were not associated with incident HCV infection.

Multivariate analysis identified illicit drug use as a significant risk for incident HCV infection after adjustment for age (adjusted HR = 3.814; 95% CI: 1.447 to 10.05; $P = 0.007$) and for other variables (adjusted HR = 3.006; 95% CI: 1.092 to 8.275; $P = 0.033$) (see **Table S2, Supplemental Digital Content**, <http://links.lww.com/QAI/A479>). Injection drug users (HR = 4.672; 95% CI: 1.425 to 15.31; $P = 0.011$) and on social benefits (HR = 7.942; 95% CI: 2.370 to 26.62; $P = 0.001$) were also risk factors for incident HCV infection in multivariate analysis.

DISCUSSION

At our large urban HIV clinic in Tokyo, 21 (2.8%) HIV-infected MSM patients were newly infected with HCV during the study period, with an incidence of 9.35 per 1000 PY. The incidence of HCV infection showed statistically significant increase over the observation period, from 0 per 1000 PY in 2005–2006 to 24.9 per 1000 PY in 2011–2012. Most incident HCV cases were noninjection drug users, as 17 (81%) patients were not identified as using injection drugs. The incidence of new HCV infection was >3-folds higher in any illicit drug users than nonusers, with estimated incidence of 16.6 and 4.48 per 1000 PY, respectively, and illicit drug use was identified as a significant risk factor for incident HCV infection in multivariate analysis.

To our knowledge, this is the first study in Japan and is the second in Asia to report the incidence and risk factors for incident HCV infection among HIV-infected MSM.²³ The incidence of 9.35 per 1000 PY was similar to that reported in North America and Western Europe (8.7–16.3/1000 PY) and was also very close to that of Taiwan (9.25/1000 PY).^{23–26} The results of this study demonstrated the emergence of noninjection drug-related HCV infection in HIV-1-infected MSM in resource-rich settings in Asia and support routine rescreening for HCVAb among HIV-infected MSM, in particular among drugs users, both injectors and noninjectors.

The reason for the increasing trend of incident HCV infection in HIV-infected MSM noninjection drug users remains to be elucidated. Both baseline positive HBsAg and TPHA, markers for sexual activity, were not associated with incident HCV in this study. This is probably because these variables were collected at the baseline and do not necessarily reflect the ongoing sexual activity during observation period. However, based on reports from Western Europe and North America, it is reasonable to assume that such change in the incidence is mainly because of increased practice of high-risk sexual behaviors, such as unprotected anal intercourse, group sex, and fisting (often practiced in the context of illicit drug use that can lower the pain threshold, leading to increased bleeding) among MSM with HIV-1 infection in Japan.¹⁰ Sharing of drug paraphernalia and possible intranasal/intrarectal transmission can also contribute.^{27,28} Because of the introduction of effective and tolerable antiretroviral therapy, the life expectancy and quality of life of people with HIV infection has improved substantially, which could associate with increased high-risk behavior in MSM with HIV-1 infection.^{29,30}

Several limitations need to be acknowledged. First, because this study did not count the number of HCVAb tests for each patient during each observation period, it is possible that the increasing trend of incident HCV infection is because of increasing number of HCV testing in recent years. However, most patients with incident HCV infection were tested for HCVAb in clinical practice, because they were suspected to have acute HCV infection based on elevated liver enzymes. Thus, it is highly likely that the increasing trend of HCV infection shown in this study is true for this cohort. Second, we were not able to rescreen for HCVAb for 28% of the patients with negative baseline HCVAb result. Third, the structured interview designed for data collection and chart review do not necessarily prevent underreporting of illicit drug use and injection drug use. However, underreporting to a certain degree is unavoidable with regard to issues such as illicit drugs.³¹

In conclusion, this study showed that incident HCV is increasing among mostly noninjection drug use MSM with HIV-1 infection at resource-rich setting in Asia. Illicit drug use was identified as an independent risk factor for incident HCV infection. It is important to raise awareness of noninjection drug-related HCV infection and to take appropriate measures to prevent HCV infection in this population.

ACKNOWLEDGMENTS

The authors thank Yukiko Takahashi and Fujie Negishi for their assistance in sample processing, Misao Takano for invaluable comments for the manuscript, and Akiko Nakano for the project coordination. They also thank all other clinical staff at the AIDS Clinical Center, National Center for Global Health and Medicine, for the dedicated clinical practice and patient care.

REFERENCES

1. Monto A, Schooley RT, Lai JC, et al. Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop. *Am J Gastroenterol*. 2010;105:989–1004; quiz 1988, 1005.
2. Pineda JA, Gonzalez J, Ortega E, et al. Prevalence and factors associated with significant liver fibrosis assessed by transient elastometry in HIV/hepatitis C virus-coinfected patients. *J Viral Hepat*. 2010;17:714–719.
3. Smith C, Sabin CA, Lundgren JD, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D: A:D Study. *AIDS*. 2010;24:1537–1548.
4. Sherman KE, Rouster SD, Chung RT, et al. Hepatitis C Virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. *Clin Infect Dis*. 2002;34:831–837.
5. Staples CT Jr, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. *Clin Infect Dis*. 1999;29:150–154.
6. Wandeler G, Gsponer T, Bregenzler A, et al. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. *Clin Infect Dis*. 2012;55:1408–1416.
7. Alter MJ. Prevention of spread of hepatitis C. *Hepatology*. 2002;36: S93–S98.
8. Danta M, Brown D, Bhagani S, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. *AIDS*. 2007;21:983–991.

9. Urbanus AT, van de Laar TJ, Stolte IG, et al. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. *AIDS*. 2009;23:F1–F7.
10. van de Laar T, Pybus O, Bruisten S, et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. *Gastroenterology*. 2009;136:1609–1617.
11. Macias J, Palacios RB, Claro E, et al. High prevalence of hepatitis C virus infection among noninjecting drug users: association with sharing the inhalation implements of crack. *Liver Int*. 2008;28:781–786.
12. Schmidt AJ, Rockstroh JK, Vogel M, et al. Trouble with bleeding: risk factors for acute hepatitis C among HIV-positive gay men from Germany—a case-control study. *PLoS One*. 2011;6:e17781.
13. Larsen C, Chaix ML, Le Strat Y, et al. Gaining greater insight into HCV emergence in HIV-infected men who have sex with men: the HEPAIG Study. *PLoS One*. 2011;6:e29322.
14. Rauch A, Rickenbach M, Weber R, et al. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. *Clin Infect Dis*. 2005;41:395–402.
15. Tominaga M, Kawakami N, Ono Y, et al. Prevalence and correlates of illicit and non-medical use of psychotropic drugs in Japan: findings from the World Mental Health Japan Survey 2002–2004. *Soc Psychiatry Psychiatr Epidemiol*. 2009;44:777–783.
16. Wada K. The history and current state of drug abuse in Japan. *Ann N Y Acad Sci*. 2011;1216:62–72.
17. National Center for Neurology and Psychiatry. The 2009 Nationwide General Population Survey on Drug Use and Abuse. Available at: <http://www.nenp.go.jp/nimb/pdf/h21.pdf>, in Japanese. Accessed March 31, 2013.
18. The Japanese Ministry of Health, Labour, and Welfare. Available at: <http://www.mhlw.go.jp/bunya/iyakuhin/yakubuturanyou/torikumi/dl/index-01.pdf>, in Japanese. Accessed March 31, 2013.
19. Nishijima T, Komatsu H, Higasa K, et al. Single nucleotide polymorphisms in ABCC2 associate with tenofovir-induced kidney tubular dysfunction in Japanese patients with HIV-1 infection: a pharmacogenetic study. *Clin Infect Dis*. 2012;55:1558–1567.
20. Nishijima T, Gatanaga H, Komatsu H, et al. Illicit drug use is a significant risk factor for loss to follow up in patients with HIV-1 infection at a large urban HIV clinic in Tokyo. *PLoS One*. 2013;8:e72310.
21. Gatanaga H, Hayashida T, Tanuma J, et al. Prophylactic effect of anti-retroviral therapy on hepatitis B virus infection. *Clin Infect Dis*. 2013;56:1812–1819.
22. Witt MD, Seaberg EC, Darilay A, et al. Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984–2011. *Clin Infect Dis*. 2013;57:77–84.
23. Sun HY, Chang SY, Yang ZY, et al. Recent hepatitis C virus infections in HIV-infected patients in Taiwan: incidence and risk factors. *J Clin Microbiol*. 2012;50:781–787.
24. Garg S, Taylor LE, Grasso C, et al. Prevalent and incident hepatitis C virus infection among HIV-infected men who have sex with men engaged in primary care in a Boston community health center. *Clin Infect Dis*. 2013;56:1480–1487.
25. Giraudon I, Ruf M, Maguire H, et al. Increase in diagnosed newly acquired hepatitis C in HIV-positive men who have sex with men across London and Brighton, 2002–2006: is this an outbreak? *Sex Transm Infect*. 2008;84:111–115.
26. van de Laar TJ, van der Bij AK, Prins M, et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. *J Infect Dis*. 2007;196:230–238.
27. Corson S, Greenhalgh D, Taylor A, et al. Modelling the prevalence of HCV amongst people who inject drugs: an investigation into the risks associated with injecting paraphernalia sharing. *Drug Alcohol Depend*. 2013;133:172–179.
28. Thibault V, Bara JL, Nefau T, et al. Hepatitis C transmission in injection drug users: could swabs be the main culprit? *J Infect Dis*. 2011;204:1839–1842.
29. Porter K, Babiker A, Bhaskaran K, et al. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. *Lancet*. 2003;362:1267–1274.
30. Stolte IG, Dukers NH, Geskus RB, et al. Homosexual men change to risky sex when perceiving less threat of HIV/AIDS since availability of highly active antiretroviral therapy: a longitudinal study. *AIDS*. 2004;18:303–309.
31. Magnani R, Sabin K, Saidel T, et al. Review of sampling hard-to-reach and hidden populations for HIV surveillance. *AIDS*. 2005;19(suppl 2):S67–S72.

Traditional but Not HIV-Related Factors Are Associated with Nonalcoholic Fatty Liver Disease in Asian Patients with HIV-1 Infection

Takeshi Nishijima^{1,4}, Hiroyuki Gatanaga^{1,4*}, Takuro Shimbo³, Hirokazu Komatsu⁵, Yuichi Nozaki², Naoyoshi Nagata², Yoshimi Kikuchi¹, Mikio Yanase², Shinichi Oka^{1,4}

1 AIDS Clinical Center, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan, **2** Gastroenterology/Hepatology, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan, **3** Department of Clinical Study and Informatics, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan, **4** Center for AIDS Research, Kumamoto University, Kumamoto, Japan, **5** Department of Community Care, Saku Central Hospital, Nagano, Japan

Abstract

Background: The prevalence and factors associated with nonalcoholic fatty liver disease (NAFLD) are largely unknown in HIV-1 monoinfected patients.

Methods: The present study elucidated the prevalence and factors associated with NAFLD among Asian patients with HIV-1 infection who underwent abdominal ultrasonography between January 2004 and March 2013. Diagnosis of NAFLD was based on the liver to kidney contrast and diffusion in hepatic echogenicity. Uni- and multi-variate logistic regression analyses were applied to estimate factors associated with NAFLD.

Results: 435 Asian patients free of chronic hepatitis B or C virus infection and without excessive alcohol intake were analyzed. NAFLD was diagnosed in 135 (31%) patients. Obesity (BMI >30 kg/m²) was evident in 18 (4.1%) patients, and BMI was >25 kg/m² in 103 (24%). Multivariate analysis identified higher BMI (per 1 kg/m² increment, adjusted OR = 1.198; 95% CI, 1.112–1.290; p<0.001), dyslipidemia (adjusted OR = 2.045; 95% CI, 1.183–3.538; p = 0.010), and higher ALT to AST ratio (per 1 increment, adjusted OR = 3.557; 95% CI, 2.129–5.941; p<0.001) as significant factors associated with NAFLD. No HIV-specific variables, including treatment with dideoxynucleoside analogues (didanosine, stavudine, and zalcitabine) and cumulative duration of antiretroviral therapy (ART), were associated with NAFLD.

Conclusions: The incidence of NAFLD among Asian patients with HIV-1 infection is similar to that in Western countries. NAFLD was associated with high BMI, dyslipidemia, and high ALT/AST ratio, but not with HIV-related factors. The results highlight the importance of early recognition and management of NAFLD and traditional factors associated with NAFLD for Asian patients with HIV-1 infection.

Citation: Nishijima T, Gatanaga H, Shimbo T, Komatsu H, Nozaki Y, et al. (2014) Traditional but Not HIV-Related Factors Are Associated with Nonalcoholic Fatty Liver Disease in Asian Patients with HIV-1 Infection. PLoS ONE 9(1): e87596. doi:10.1371/journal.pone.0087596

Editor: Ming-Lung Yu, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Taiwan

Received: October 22, 2013; **Accepted:** December 21, 2013; **Published:** January 31, 2014

Copyright: © 2014 Nishijima et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by a Grant-in-Aid for AIDS research from the Ministry of Health, Labor, and Welfare, Japan (H22-AIDS-001), and the Global Center of Excellence Program, the Ministry of Education, Science, Sports and Culture of Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: higatana@acc.nccgm.go.jp

Introduction

Nonalcoholic fatty liver disease (NAFLD) is characterized by the presence of fat infiltration in the liver in the absence of excessive alcohol consumption or other causes of liver disease, such as viral hepatitis, and is considered the most common cause of fatty liver [1]. NAFLD is a major health issue since it can lead to fibrosis, cirrhosis, liver cancer, and mortality [2]. Although the prevalence of NAFLD seems increasing in parallel with the current epidemic of obesity, it varies among the general population according to the geographical area; for example, the prevalence of NAFLD in the US ranges from 10 to 46% [3,4], whereas in Asia it is 5–30% [5].

In the general population, obesity, type 2 diabetes mellitus, dyslipidemia, and metabolic syndrome are established conditions

associated with NAFLD [6]. In addition to abovementioned environmental risk factors, genetic factors are also associated with the incidence of NAFLD [7]. However, only two studies (one from Italian metabolic clinic and the other from American naval hospital) have previously examined the prevalence and associated factors with NAFLD in patients infected with HIV-1 only (those without chronic hepatitis C virus (HCV) infection) [8,9]. At this stage, it is unknown whether variables specific to HIV-1 infection, such as HIV-1 viral load and cumulative years of antiretroviral therapy (ART) are associated with NAFLD. Although the use of so called “D drugs”: dideoxynucleoside analogues [didanosine (ddI), stavudine (d4T), and zalcitabine (ddC)], a subgroup of antiretroviral agents nucleoside reverse transcriptase inhibitors (NRTI), is

reported to be associated with NAFLD, others have argued against such relation [8,9].

Liver diseases are important causes of morbidity and mortality among patients with HIV-1 infection [10–12], especially following the wide availability of ART and substantial improvement in prognosis of such patients [13]. Currently, there is no information on the prevalence and associated factors related to NAFLD among patients with HIV-1 infection in Asia, the region with the second largest number of patients with HIV-1 infection. The present study was designed to elucidate the prevalence and associated factors, including D drug use, with NAFLD in Asian patients with HIV-1 infection.

Methods

Ethics statement

This study was approved by the Human Research Ethics Committee of the National Center for Global Health and Medicine, Tokyo. Each participant provided a written informed consent for the clinical and laboratory data to be used and published for research purposes. The study was conducted according to the principles expressed in the Declaration of Helsinki.

Study design

We performed a single-center cross-sectional study of HIV-1-infected patients using the abdominal ultrasonography data and medical records at the National Center for Global Health and Medicine, Tokyo, Japan. Our facility is one of the largest clinics for patients with HIV infection in Japan with approximately 3,500 registered patients [14]. The study population was HIV-infected patients, aged >17 years, who underwent routine abdominal ultrasonography conducted by certified medical technologists at the Physiological Examination Unit of the hospital, between January 1, 2004 and March 31, 2013. The following exclusion criteria were employed in this study; 1) HCV or hepatitis B virus (HBV) infection defined by positive hepatitis C antibody or positive hepatitis B surface antigen, respectively, 2) use of injection drugs, 3) hemophilia, because all HIV-infected hemophiliacs in Japan were exposed to HCV through contaminated blood products [15], and 4) alcohol consumption >20 g of ethanol per day for males and >10 g/day for females. Fatty liver was diagnosed based on hyperechogenicity of the liver compared to renal cortex and diffusion in hepatic echogenicity [8,16,17]. The ultrasonographic images and diagnosis were double-checked and confirmed by radiologists, hepatologists, or gastroenterologists. If abdominal ultrasonography was conducted more than once during the study period, the latest data were used for the study.

Measurements

The potential risk factors for NAFLD were selected according to previous studies and collected from the medical records [18,19], together with the basic demographic data. These factors included age, sex, race, body weight, body mass index (BMI) = {bodyweight (kg)/[height (m)]²}, and presence or absence of other medical conditions [diabetes mellitus, defined by use of glucose-lowering agents or fasting plasma glucose \geq 126 mg/dl or plasma glucose \geq 200 mg/dl on two different days, dyslipidemia, defined by current treatment with lipid-lowering agents or two successive measurements of either low-density lipoprotein cholesterol (LDL-C) >140 mg/dl, high-density lipoprotein cholesterol (HDL-C) <40 mg/dl, total cholesterol (TC) >240 mg/dl, triglyceride (TG) >500 mg/dl, and hypertension defined by current treatment with antihypertensive agents or two successive measurements of systolic

blood pressure \geq 140 mmHg or diastolic blood pressure \geq 90 mmHg at the clinic]. Data on smoking status and alcohol consumption were collected through a structured interview conducted at the first visit as part of routine clinical practice by the nurses specializing at the HIV outpatient care. Patients were divided into three groups according to the smoking status: non-smokers, low (<20 cigarettes/day) and heavy smokers (\geq 20 cigarettes/day). They were also divided according to alcohol consumption into two groups: non-drinkers and light drinkers (<20 g ethanol/day for men and <10 g ethanol/day for women). The values of alanine aminotransferase (ALT), aspartate aminotransferase (AST), TC, LDL-C, HDL-C, and TG within three months and closest to the day ultrasonography was conducted were collected. HIV-specific variables, such as CD4 cell count, HIV viral load, ART-experienced or ART-naïve, ART regimen at ultrasonography, history of AIDS, and duration of ART were also collected. The duration of D drugs use, as a possible risk factor for NAFLD, was collected, regardless of continuation of these drugs at the time of abdominal ultrasonography [9,20]. Patients were divided into four groups according to duration of treatment with D drugs; no D drugs use, <1 year exposure, 1–3 years of use, and >3 years of use. In our clinic, it is customary for the patient to visit the clinic once a month before the initiation of ART and until the suppression of HIV-1 viral load, but the visit interval is extended up to every three months after viral load suppression.

Statistical analysis

Baseline characteristics were compared between patients with and without NAFLD, using the Student's *t*-test or χ^2 test (Fisher's exact test) for continuous or categorical variables, respectively. Univariate logistic regression analysis was used to identify factors associated with NAFLD. Basic demographics, such as age and sex, and variables with *p* values <0.05 in univariate analysis were entered into multivariate logistic regression models. ALT, and TG and LDL-C were not added to the model, based on their multicollinearity with ALT to AST ratio and dyslipidemia, respectively. Statistical significance was defined as two-sided *p* value <0.05. We used the odds ratio (OR) and 95% confidence interval (95%CI) to estimate the association of each variable with NAFLD. All statistical analyses were performed with The Statistical Package for Social Sciences ver. 20.0 (SPSS, Chicago, IL).

Results

Of the total of 895 patients with HIV-1 infection who underwent abdominal ultrasonography during the study period, 435 were included in the analysis (Figure 1). NAFLD was diagnosed by abdominal ultrasonography in 135 cases, with a prevalence of 31%. None of these patients had any ultrasonographic finding compatible with cirrhosis. Table 1 shows the characteristics of the study population, patients with NAFLD, and those without NAFLD. The study patients were mostly East Asian males with maintained CD4 count [median 349/ μ l, interquartile range (IQR) 203–512], and approximately half of the patients had suppressed viral load. Obesity (BMI >30 kg/m²) was noted in 18 (4.1%) patients, and BMI was >25 kg/m² in 103 (24%). Body weight was significantly heavier in patients with NAFLD (median 71 kg, IQR 61–78 kg), compared with non-NAFLD (median 61 kg, IQR 55–68 kg, *p*<0.001), as was BMI (median 25, IQR 21.7–27.5 versus median 21.5, IQR 20–23.3, *p*<0.001). Dyslipidemia (*p*<0.001), hypertension (*p*=0.019), high ALT (*p*=0.017), high LDL-C (*p*=0.041), hypertriglyceridemia (*p*=0.008), and high CD4 count (*p*=0.001) were significantly more common in




Figure 1. Patient enrollment process.
doi:10.1371/journal.pone.0087596.g001

patients with NAFLD than those without (Table 1). On the other hand, history of D drug use and cumulative years of ART were not significantly different between the two groups.

Univariate analysis showed a significant association between NAFLD and the following non-HIV specific variables (Table 2): higher BMI (per 1 kg/m² increment, OR = 1.282; 95% CI, 1.197–1.373; $p < 0.001$), dyslipidemia (OR = 2.475; 95% CI, 1.594–3.842; $p < 0.001$), hypertension (OR = 1.818; 95% CI, 1.117–2.961; $p = 0.016$), ALT to AST ratio (per 1 increment, OR = 4.831; 95% CI, 3.073–7.594; $p < 0.001$), higher ALT (per 10 IU/l increment, OR = 1.027; 95% CI, 1.002–1.053; $p = 0.034$), higher triglyceride (per 10 mg/dl increment, OR = 1.021; 95% CI, 1.005–1.038; $p = 0.010$), and higher LDL-C (per 10 mg/dl increment, OR = 1.096; 95% CI, 1.003–1.196; $p = 0.042$). Among HIV-specific variables, only higher CD4 count was associated with NAFLD (per 1/ μ l increment, OR = 1.001; 95% CI, 1.001–1.002; $p = 0.002$) (Table 3). On the other hand, older age (per 1 year increment, OR = 0.996; 95% CI, 0.980–1.013; $p = 0.668$) and diabetes mellitus (OR = 1.577; 95% CI, 0.657–3.784; $p = 0.308$) were not associated with NAFLD. Compared to no D drug use, history of D drug use was not associated with NAFLD (Any to <1 year of D drug use, $n = 42$, OR = 0.956; 95% CI, 0.476–1.919; $p = 0.899$) (1 to 3 years of D drug use, $n = 46$, OR = 1.137; 95% CI, 0.592–2.184; $p = 0.699$) (> 3 years of D drug use, $n = 40$, OR = 0.533; 95% CI, 0.237–1.200; $p = 0.129$) (Table 3).

Among patients treated with D drugs ($n = 128$), the median time period since withdrawal was 3.46 years (IQR 1.03–6.29). Compared to treatment-naïve patients, ART use was not associated with NAFLD as well (<2 year of ART exposure,

$n = 80$, OR = 1.110; 95% CI, 0.620–1.985; $p = 0.726$) (2 to 6 years of ART exposure, $n = 100$, OR = 0.941; 95% CI, 0.541–1.637; $p = 0.830$) (>6 year of ART exposure, $n = 103$, OR = 1.135; 95% CI, 0.664–1.943; $p = 0.643$) (Table 3).

Multivariate analyses identified the following variables as independently associated with NAFLD: BMI (per 1 kg/m² increment, adjusted OR = 1.198; 95% CI, 1.112–1.290; $p < 0.001$), dyslipidemia (adjusted OR = 2.045; 95% CI, 1.183–3.538; $p = 0.010$), ALT to AST ratio (per 1 increment, adjusted OR = 3.557; 95% CI, 2.129–5.941; $p < 0.001$) (Table 4).

Discussion

To our knowledge, this is the first study that investigated the prevalence and associated factors of NAFLD in Asian patients with HIV-1 infection, and is the largest study that focused on NAFLD in patients with HIV-1 mono-infection (without chronic hepatitis C infection). The prevalence of NAFLD in this study was 31%, which is comparable to 31% at the Naval hospital in San Diego, US, and 36.9% at the metabolic clinic in Modena, Italy [8,9]. Multivariate analysis indicated that traditional predictors for NAFLD in the general population, such as higher BMI, dyslipidemia, and ALT to AST ratio [6], were significantly associated with NAFLD, whereas HIV-specific variables, including history of D drug use and cumulative years of ART, were not associated with NAFLD.

Our result of nearly one third of Asian patients with HIV-1 mono-infection have NAFLD highlights the importance of screening for NAFLD among this patient population, due to the potential progression of NAFLD to liver fibrosis, cirrhosis, and liver cancer [2,21]. In addition, the finding that higher BMI,

Table 1. Basic demographics of the entire study population, patients with NAFLD and without NAFLD.

	Total (n = 435)	NAFLD (n = 135)	No NAFLD (n = 300)	p ^a
Age (years) [†]	40 (35–50)	41 (36–48)	40 (34–55)	0.669
Male sex, n (%)	406 (93)	129 (96)	277 (92)	0.299
Body weight (kg) [†]	63 (57–73)	71 (61–78)	61 (55–68)	<0.001
Body mass index, (kg/m ²) [†]	22.1 (20.2–24.9)	25 (21.7–27.5)	21.5 (20–23.3)	<0.001
Body mass index >25 kg/m ² , n (%)	103 (24)	64 (49)	39 (13)	<0.001
Body mass index >30 kg/m ² , n (%)	18 (4.1)	16 (12)	2 (1)	<0.001
East Asian origin, n (%)	424 (98)	133 (99)	291 (97)	0.515
Diabetes mellitus, n (%)	22 (5)	9 (7)	13 (4)	0.345
Dyslipidemia, n (%)	120 (28)	55 (41)	65 (22)	<0.001
Hypertension, n (%)	86 (20)	36 (27)	50 (17)	0.019
ALT (IU/l) [†]	26 (17–47)	47 (25–80)	22 (16–33)	0.017
AST (IU/l) [†]	25 (19–37)	31 (21–50)	23 (18–31)	0.152
ALT to AST ratio [†]	1.05 (0.8–1.42)	1.42 (1.02–1.76)	1 (0.74–1.21)	<0.001
Low-density lipoprotein cholesterol (mg/dl) [†]	102 (85–126)	111 (90–129)	101 (83–125)	0.041
High-density lipoprotein cholesterol (mg/dl) [†]	44 (35–52)	43 (34–52)	44 (35–54)	0.701
Triglyceride (mg/dl) [†]	162 (104–233)	189 (125–254)	149 (96–226)	0.008
Total cholesterol (mg/dl) [†]	175 (150–205)	179 (151–208)	177 (149–226)	0.202
Smoking status, by no. of cigarettes per day				0.244
None, n (%)	247 (57)	84 (62)	163 (55)	
<20, n (%)	82 (19)	20 (15)	62 (21)	
≥20, n (%)	105 (24)	31 (23)	74 (25)	
Alcohol consumption				1.000
None, n (%)	209 (48)	65 (48)	144 (48)	
Moderate (<20 g/day for men, <10 g/day for women), n (%)	226 (52)	70 (52)	156 (52)	
HIV-specific variables				
CD4 cell count (cells/μL) [†]	349 (203–512)	377 (230–591)	338 (172–480)	0.001
HIV load (log ₁₀ copies/mL) [†]	1.70 (1.70–4.45)	1.70 (1.70–4.36)	1.70 (1.70–4.52)	0.508
HIV load <50 copies/mL, n (%)	227 (52)	73 (55)	154 (52)	0.602
Homosexual contact, n (%)	377 (87)	120 (89)	257 (86)	0.446
History of ddl/ddC/d4T exposure, n (%)	128 (29)	37 (27)	91 (30)	0.571
ART duration (years) [†]	1.4 (0–5.6)	1.4 (0–6.1)	1.6 (0–5.4)	0.844
Current antiretroviral therapeutic regimen				
Ritonavir-boosted PI plus 2NRTIs, n (%)	186 (43)	58 (43)	128 (43)	1.000
NNRTI plus 2NRTIs, n (%)	44 (10)	14 (10)	30 (10)	1.000
Treatment naïve, n (%)	152 (35)	46 (34)	106 (35)	0.829
History of AIDS, n (%)	156 (36)	51 (38)	105 (35)	0.590

[†]Data are median (interquartile range). Four missing values in variable HIV load <50 copies/mL.

^aχ² test or Fisher's exact test was used for categorical data, and Student's *t* test for continuous variables.

NAFLD, nonalcoholic fatty liver disease; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ddl, didanosine; ddC, zalcitabine; d4T, stavudine; ART, antiretroviral therapy; PI, protease inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; AIDS, acquired immunodeficiency syndrome.

doi:10.1371/journal.pone.0087596.t001

dyslipidemia, and ALT to AST ratio were associated with NAFLD warrants aggressive approach to life-style changes and keeping optimal body weight, as well as the management of dyslipidemia. This is particularly important because the metabolic syndrome, obesity, type 2 diabetes mellitus, and dyslipidemia are widely prevalent and are increasing among the general population in Asia [5]. Our study identified obesity in 4.1% of the study population (BMI >30 kg/m²), the number that is similar to that reported from the Italian metabolic clinic (4.9%), although much lower

than that reported in US (14.8%) [8,9]. Our results showed that the prevalence of NAFLD in Asian patients with HIV-1 infection is as high as that reported in the above two studies, and warrants the need for paying attention to this disease in Asian patients with HIV-1 infection.

Interestingly, the present study did not identify HIV-specific variables, especially treatment with D drugs, to be associated with NAFLD. D drugs (dideoxynucleoside analogues; ddI, d4T, and ddC), a subgroup of NRTIs, inhibit mitochondrial DNA (mDNA)

Table 2. Univariate analysis to estimate the associations of non HIV-specific variables with nonalcoholic fatty liver disease.

	Odds ratio	95%CI	P value
Male sex	1.785	0.710–4.491	0.218
Age per 1 year increment	0.996	0.980–1.013	0.668
Body mass index per 1 kg/m ² increment	1.282	1.197–1.373	<0.001
Alcohol consumption			
No drinking	Reference	Reference	Reference
Ethanol <20 g/day for men, <10 g/day for women	0.994	0.662–1.493	0.977
Smoking status			
Non smoker	Reference	Reference	Reference
<20 cigarettes/day	0.626	0.354–1.105	0.106
≥20 cigarettes/day	0.813	0.495–1.334	0.412
Diabetes mellitus	1.577	0.657–3.784	0.308
Dyslipidemia	2.475	1.594–3.842	<0.001
Hypertension	1.818	1.117–2.961	0.016
ALT to AST ratio per 1 increment	4.831	3.073–7.594	<0.001
ALT per 10 IU/l increment	1.027	1.002–1.053	0.034
AST per 10 IU/l increment	1.034	0.986–1.084	0.169
Triglyceride per 10 mg/dl increment	1.021	1.005–1.038	0.010
Low-density lipoprotein cholesterol per 10 mg/dl increment	1.096	1.003–1.196	0.042
Total cholesterol per 10 mg/dl increment	1.037	0.981–1.096	0.202
High-density lipoprotein cholesterol per 10 mg/dl increment	1.032	0.878–1.215	0.700

CI, confidence interval; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
doi:10.1371/journal.pone.0087596.t002

Table 3. Univariate analysis to estimate the association of HIV-specific variables with nonalcoholic fatty liver disease.

	Odds ratio	95%CI	P value
ddl/ddC/d4T use	0.867	0.552–1.362	0.536
No ddl/ddC/d4T use (n = 307)	Reference	Reference	
<1 year of ddl/ddC/d4T use (n = 42)	0.956	0.476–1.919	0.899
1–3 years of ddl/ddC/d4T use (n = 46)	1.137	0.592–2.184	0.699
>3 years of ddl/ddC/d4T use (n = 40)	0.533	0.237–1.200	0.129
ART exposure			
Treatment naïve (n = 152)	Reference	Reference	
<2 years of ART exposure (n = 80)	1.110	0.620–1.985	0.726
2–6 years of ART exposure (n = 100)	0.941	0.541–1.637	0.830
>6 years of ART exposure (n = 103)	1.135	0.664–1.943	0.643
CD4 count per 1/μl increment	1.001	1.001–1.002	0.002
HIV viral load per log ₁₀ /ml increment	0.955	0.833–1.094	0.507
HIV viral load <50 copies/ml	1.138	0.755–1.715	0.538
History of AIDS	1.128	0.740–1.718	0.576
Treatment naïve	0.946	0.617–1.450	0.799

OR, odds ratio; CI, confidence interval; ddl, didanosine; ddC, zalcitabine; d4T, stavudine; ART, antiretroviral therapy; AIDS, acquired immunodeficiency syndrome.
doi:10.1371/journal.pone.0087596.t003

polymerase γ, resulting in depletion of mtDNA in the liver [22], and causes mitochondria toxicity with potential fatal lactic acidosis and hepatic steatosis [23–25]. However, previous studies on patients with HIV mono-infection (without chronic hepatitis C infection) showed conflicting results with regard to the relation between NAFLD and D drug use [8,9]. The present study also did not find significant association between D drug use and NAFLD. Considering that D drugs are rarely used in resource-rich settings and their use is also rapidly decreasing in resource-limited settings, especially after 2010 revision of WHO guidelines, which eliminated d4T from the first line therapy (http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf), it is probably plausible to say that more focus needs to be put on traditional

Table 4. Multivariate analysis of independent variables associated with nonalcoholic fatty liver disease (n = 408).

	Adjusted OR	95%CI	P value
Male sex	1.953	0.640–5.966	0.240
Age 1 year increment	1.005	0.983–1.027	0.672
Body mass index per 1 kg/m ² increment	1.198	1.112–1.290	<0.001
Dyslipidemia	2.045	1.183–3.538	0.010
ALT to AST ratio per 1 increment	3.557	2.129–5.941	<0.001
Hypertension	0.959	0.510–1.805	0.897
CD4 count per 1/μl increment	1.001	0.999–1.002	0.336

OR, odds ratio; CI, confidence interval; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
doi:10.1371/journal.pone.0087596.t004

predictors for NAFLD, such as obesity and dyslipidemia, rather than D drug use when screening and managing NAFLD in patients with HIV-1 infection.

There are several limitations to our study. First, the diagnosis of NAFLD was achieved by use of ultrasonography, although histological confirmation of NAFLD by liver biopsy is considered the gold standard [16]. Because it is also difficult to grade the severity of fat infiltration in the liver by ultrasonography, the present study could not distinguish nonalcoholic steatohepatitis (NASH), the more severe form of NAFLD [6,16,19]. However, liver biopsy is an invasive and costly procedure. Compared to histopathology and other imaging devices, such as computed tomography (CT) and magnetic resonance imaging (MRI), the reliability and accuracy of ultrasonography in the diagnosis of fatty liver has been well-established [16]. Other advantages of ultrasonography includes low cost, safety, and availability, compared with liver biopsy, CT, and MRI [16]. Second, because the study population comprised of mostly males, the results of the present study might not apply to female patients. Third, we cannot exclude possible overestimation of the prevalence of NAFLD in this study since the study population included patients who underwent abdominal ultrasonography in clinical practice. However, considering that the two previous reports on NAFLD in HIV-monoinfected patients included only patients with dyslipidemia and hyperglycemia at the metabolic clinic [9], and almost exclusively military personnel at the naval hospital [8], respectively, the present study confers clinically useful information

References

- Lazo M, Clark JM (2008) The epidemiology of nonalcoholic fatty liver disease: a global perspective. *Semin Liver Dis* 28: 339–350.
- Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, et al. (2005) The natural history of nonalcoholic fatty liver disease: a population-based cohort study. *Gastroenterology* 129: 113–121.
- Vernon G, Baranova A, Younossi ZM (2011) Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. *Aliment Pharmacol Ther* 34: 274–285.
- Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, et al. (2011) Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. *Gastroenterology* 140: 124–131.
- Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ, et al. (2007) How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? *J Gastroenterol Hepatol* 22: 788–793.
- Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, et al. (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. *Hepatology* 55: 2005–2023.
- Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, et al. (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. *Nat Genet* 40: 1461–1465.
- Crum-Cianflone N, Dilay A, Collins G, Asher D, Campin R, et al. (2009) Nonalcoholic fatty liver disease among HIV-infected persons. *J Acquir Immune Defic Syndr* 50: 464–473.
- Guaraldi G, Squillace N, Stentarelli C, Orlando G, D'Amico R, et al. (2008) Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. *Clin Infect Dis* 47: 250–257.
- (2010) Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996–2006: collaborative analysis of 13 HIV cohort studies. *Clin Infect Dis* 50: 1387–1396.
- Lewden C, May T, Rosenthal E, Burty C, Bonnet F, et al. (2008) Changes in causes of death among adults infected by HIV between 2000 and 2005: The “Mortalite 2000 and 2005” surveys (ANRS EN19 and Mortavic). *J Acquir Immune Defic Syndr* 48: 590–598.
- Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, et al. (2006) Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. *Arch Intern Med* 166: 1632–1641.
- (2008) Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. *The Lancet* 372: 293–299.
- Nishijima T, Komatsu H, Higasa K, Takano M, Tsuchiya K, et al. (2012) Single nucleotide polymorphisms in ABCG2 associate with tenofovir-induced kidney tubular dysfunction in Japanese patients with HIV-1 infection: a pharmacogenetic study. *Clin Infect Dis* 55: 1558–1567.
- Tsukada K, Sugawara Y, Kaneko J, Tamura S, Tachikawa N, et al. (2011) Living donor liver transplantations in HIV- and hepatitis C virus-coinfected hemophiliacs: experience in a single center. *Transplantation* 91: 1261–1264.
- Hernaiz R, Lazo M, Bonekamp S, Kamel I, Brancati FL, et al. (2011) Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. *Hepatology* 54: 1082–1090.
- Rumack CM, Wilson SR, Charboneau JW, Johnson JM (2005) *Diagnostic Ultrasound*. Vol 1. 3rd ed. St Louis: Elsevier Mosby.
- Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, et al. (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. *Gastroenterology* 142: 1592–1609.
- Lemoine M, Serfaty L, Capeau J (2012) From nonalcoholic fatty liver to nonalcoholic steatohepatitis and cirrhosis in HIV-infected patients: diagnosis and management. *Curr Opin Infect Dis* 25: 10–16.
- Zeremski M, Talal AH (2006) Dideoxynucleoside analogues should be used cautiously in patients with hepatic steatosis. *Clin Infect Dis* 43: 373–376.
- Farrell GC, Larter CZ (2006) Nonalcoholic fatty liver disease: from steatosis to cirrhosis. *Hepatology* 43: S99–S112.
- Walker UA, Bauerle J, Laguno M, Murillas J, Mauss S, et al. (2004) Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. *Hepatology* 39: 311–317.
- Lewis W, Day BJ, Copeland WC (2003) Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. *Nat Rev Drug Discov* 2: 812–822.
- Claessens YE, Cariou A, Monchi M, Soufir L, Azoulay E, et al. (2003) Detecting life-threatening lactic acidosis related to nucleoside-analog treatment of human immunodeficiency virus-infected patients, and treatment with L-carnitine. *Crit Care Med* 31: 1042–1047.
- Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA (2000) Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. *Ann Intern Med* 133: 192–196.

derived from routine clinical practice with comparatively unrestricted patient population at a large urban HIV clinic.

In conclusion, the present study demonstrated that the prevalence of NAFLD in Asian patients with HIV-1 infection was 31%, which is comparable to the studies from Western Europe and US. NAFLD was significantly associated with traditional predictors for NAFLD, such as higher BMI, dyslipidemia, and ALT to AST ratio, but not with any HIV-specific variable, including history of D drug use and cumulative years of ART. The results highlight the importance of early recognition and management of NAFLD and its traditional predictors, in order to prevent further progression of NAFLD in Asian patients with HIV-1 infection.

Acknowledgments

The authors thank Motoshi Maejima, a senior staff at the Physiological Examination Unit, Mikiko Ogata, and Michiyo Ishisaka for invaluable contribution to the study. The authors also thank Akiko Nakano for supporting this study as a research coordinator, and all the clinical staff at the AIDS Clinical Center for their help in the completion of this study.

Author Contributions

Conceived and designed the experiments: TN TS HK. Performed the experiments: TN YN MY. Analyzed the data: TN HG TS HK SO. Contributed reagents/materials/analysis tools: YN NN YK MY SO. Wrote the paper: TN HG TS HK SO.

Impact of HIV Infection on Colorectal Tumors: A Prospective Colonoscopic Study of Asian Patients

Yohei Hamada, MD,* Naoyoshi Nagata, MD,† Takeshi Nishijima, MD,*‡ Takuro Shimbo, MD, PhD,§ Naoki Asayama, MD,† Yoshihiro Kishida, MD,† Katsunori Sekine, MD,† Shohei Tanaka, MD,† Tomonori Aoki, MD,† Kazuhiro Watanabe, MD,† Junichi Akiyama, MD,† Toru Igari, MD,|| Masashi Mizokami, MD, PhD,¶ Naomi Uemura, MD, PhD,# and Shinichi Oka, MD, PhD*‡

Background: Non-AIDS defining cancer has recently become a major problem in HIV-infected patients. Little has been reported on whether HIV infection is a risk factor for colorectal adenoma, especially in Asians.

Methods: The study was conducted under a prospective cross-sectional design and included all adults who underwent colonoscopy. Subjects were matched by age and sex to compare the prevalence of colorectal adenoma, adenocarcinoma, polyps, and other tumors. Detailed risk factors were assessed, including lifestyle habits, medications, comorbidities, gastrointestinal symptom rating scale, HIV-associated factors, and human papillomavirus infection. To evaluate the effects of HIV infection on adenoma, the odds ratio (OR) was estimated by multivariate logistic regression.

Results: A total of 177 HIV-infected patients and 177 controls were selected for analysis. No significant difference was noted in the prevalence of adenoma ($n = 29$ vs. 40 , $P = 0.14$). Multivariate analysis adjusted by baseline demographics and risk factors showed that HIV is not associated with increased risk of adenoma (adjusted OR = 0.66 , $P = 0.16$). Kaposi's sarcoma was more common in HIV-infected patients ($n = 6$ vs. 0 , $P = 0.03$). Among HIV-infected patients, advanced age was an independent and significant risk factor for adenoma (adjusted OR = 2.28 , $P < 0.01$). CD4 count, HIV-

RNA, history of antiretroviral treatment, and oncogenic human papillomavirus infection were not risk factors for adenoma.

Conclusions: HIV infection was not identified as risk for adenoma in Asian patients. However, advanced age was independently associated with increased risk of adenoma. HIV-infected patients should not miss screening opportunity for colorectal adenoma and other gastrointestinal malignancies.

Key Words: colorectal cancer, colorectal adenoma, oncogenic HPV infection, Japan, gastrointestinal malignancy

(*J Acquir Immune Defic Syndr* 2014;65:312–317)

INTRODUCTION

The introduction of highly active antiretroviral therapy (HAART) has significantly improved the morbidity and mortality of HIV-infected patients.^{1,2} However, the incidence of non-AIDS defining cancer has increased with prolongation of life expectancy of HIV-infected patients.^{3–6}

Colorectal cancer is the third most commonly diagnosed cancer in male patients and the second in female patients, and a major cause of death worldwide.⁷ To prevent the development of colorectal cancer and death, removal of premalignant lesion, adenoma, is effective, and screening is recommended in patients aged 50 years and older.^{8–11} Recent studies from western countries have suggested that higher incidence of colonic adenoma in patients with HIV infection compared with the general population.^{12–14} Furthermore, HIV-infected patients are at high risk of oncogenic human papillomavirus (HPV) infection, and the potential role of HPV infection in the development of colorectal cancer has been suggested.^{15–17} However, little is known about the risk of adenoma in HIV-infected patients compared with the general population.

In the past, the incidence of colorectal cancer was lower in Asia compared with Western countries.¹⁸ However, the incidence has increased lately in Asian countries, including Japan, and is currently comparable with that in western countries.^{18,19} Nevertheless, all previous studies on colorectal adenoma in HIV-infected patients were only from the United States, and there are no available data in Asia.^{12–14} This study reports the findings of a prospective cross-sectional colonoscopic study that compared the prevalence of colorectal

Received for publication July 9, 2013; accepted September 20, 2013.

From the *AIDS Clinical Center and †Department of Gastroenterology and Hepatology, National Center for Global Health and Medicine, Tokyo, Japan; ‡Center for AIDS Research, Kumamoto University, Kumamoto, Japan; §Research and Informatics, International Clinical Research Center Research Institute, and ||Pathology Division of Clinical Laboratory, National Center for Global Health and Medicine, Tokyo, Japan; and ¶The Research Center for Hepatitis and Immunology, Department of Gastroenterology and Hepatology, and #Department of Gastroenterology and Hepatology, National Center for Global Health and Medicine, Kohnodai Hospital, Chiba, Japan.

The authors have no conflicts of interest to disclose.

Supported by Grants-in Aid for AIDS research from the Japanese Ministry of Health, Labor, and Welfare (H23-AIDS-001) and the Global Center of Excellence Program (Global Education and Research Center Aiming at the Control of AIDS) from the Japanese Ministry of Education, Science, Sports, and Culture.

Correspondence to: Naoyoshi Nagata, MD, Department of Gastroenterology and Hepatology, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo 162-8655, Japan (e-mail: nnagata_ncgm@yahoo.co.jp).

Copyright © 2013 by Lippincott Williams & Wilkins

adenoma in HIV-infected patients with HIV-negative patients in Japan.

METHODS

Study Design, Setting, and Participants

We conducted a prospective cross-sectional single-center study in adults who underwent colonoscopy between September 2009 and July 2012 at the endoscopy unit of the National Center for Global Health and Medicine (NCGM). NCGM has one of the largest clinics for patients with HIV infection in Japan with more than 3500 registered patients as of May 2013. The institutional review board at NCGM approved this study. The study was conducted according to the principles expressed in the Declaration of Helsinki.

The following inclusion criteria were used in this study: (1) aged 18 years or older, (2) independent in activities of daily living, (3) able to understand written documents and to write, and (4) asymptomatic but desired screening for colorectal cancer, or presented with continuous or intermittent lower gastrointestinal (GI) symptoms. The following exclusion criteria were used in this study: (1) contraindication or patient refusal of total colonoscopy, (2) colonoscopy for follow-up evaluation during the study period, and (3) previous diagnosis of either adenoma or adenocarcinoma. All inclusion and exclusion criteria were fulfilled before patients were enrolled in the study. Each HIV-infected patient was matched with 1 HIV-negative patient based on age in 5-year age-bands and sex.

Clinical Factors

A detailed questionnaire was completed at the endoscopy unit on the same day of colonoscopy. Patients were asked about their (1) lifestyle habits (smoking history and alcohol consumption), (2) medications [nonsteroidal anti-inflammatory drugs (NSAIDs) and low-dose aspirin], and (3) comorbidities (hypertension, diabetes mellitus, and coronary heart disease) in a face-to-face interview with the medical staff. With regard to medication history, prescriptions and medical records were reviewed in addition to information provided by the patients to avoid omissions. The survey form included photographs of all these oral drugs, which are approved in Japan. Regular use of medication was defined as oral administration starting at least 1 year before the interview. The smoking index was evaluated among ever and daily smokers and was defined as the number of cigarettes per day multiplied by the number of smoking years. Then, smoking index was categorized into nil, <400, 400–799, and >800. Alcohol consumption was calculated and categorized into nondrinker, light (1–180 g/wk), moderate (181–360 g/wk), and heavy drinker (>360 g/wk). To evaluate lower GI symptoms, the GI symptom rating scale rating on a 7-graded Likert scale was used.^{20,21} The GI symptom rating scale consists of 15 questions covering lower GI symptoms: increased flatus, decreased passage of stools, increased passage of stools, loose stools, hard stools, urgent

need for defecation, and feeling of incomplete evacuation. Positive symptoms were defined as score ≥ 3 .

For HIV-infected patients, CD4 cell count, HIV viral load, history of HAART, and sexual behavior were also obtained. CD4 cell counts within 1 week and HIV-RNA viral load within 1 month were used in the analysis, and positive result for real-time HIV-RNA was defined as ≥ 40 copies per milliliter. Sexual behavior was defined as men who have sex with men or heterosexuality. Furthermore, immediately following colonoscopy, rectal swabs (DNAPAP cervical sampler; Qiagen, Gaithersburg, MD) were obtained. Rectal samples were analyzed for HPV-DNA and genotyping by means of polymerase chain reaction-invasion assay as described previously.²² HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59 were defined as oncogenic HPV.²³

Diagnosis of Colorectal Adenoma, Adenocarcinoma, and Non-Neoplastic Polyps

After intestinal lavage with 2 L of solution containing polyethylene glycol, colonoscopy was performed by experienced gastroenterologists by using an electronic high-resolution video endoscope (model CFH260; Olympus Optical, Tokyo, Japan). The location of all lesions was recorded in electronic endoscopic database (Olympus Medical Systems; Solemio Endo). All visualized lesions were biopsied and histologically assessed by experienced pathologists.

Statistical Analysis

Baseline characteristics were compared using the unpaired Student *t* test or χ^2 test (Fisher exact test) for quantitative or qualitative variables, respectively. To estimate the effect of HIV infection on adenoma, multivariate logistic regression analysis was performed adjusted for age, sex, and possible risk factors for adenoma (these included smoking and alcohol consumption, diabetes mellitus, coronary artery diseases, and NSAIDs and aspirin use). In addition, we conducted uni- and multivariate logistic regression analysis in HIV-infected patients to elucidate the impact of other factors on adenoma related to HIV-infected patients (CD4 count, HIV-RNA, history of HAART, sexual behavior, and oncogenic HPV infection).

Statistical significance was defined as 2-sided *P* values < 0.05. We estimated the odds ratios (ORs) and 95% confidence intervals (CIs). All statistical analyses were performed using the Statistical Package for Social Sciences version 17.0 (SPSS, Chicago, IL).

RESULTS

Participants

A total of 177 HIV-infected patients and 177-HIV-negative controls were selected for analysis after the application of the aforementioned exclusion criteria and age matching (Fig. 1). The baseline characteristics are listed in Table 1. The study subjects were mostly men, Asians, and comparatively young. HIV-infected patients were more likely to be smokers